𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Blood and serum substances for markers of prostate cancer

✍ Scribed by Chris H. Bangma; Paul C.M.S. Verhagen

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
124 KB
Volume
51
Category
Article
ISSN
1059-910X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Serum markers for monitoring of prostati
Serum markers for monitoring of prostatic carcinoma
✍ Polito, Mario; Minardi, Daniele; Recchioni, Alberto; Giannulis, Ioannis; De Sio, πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 144 KB πŸ‘ 1 views

## BACKGROUND. Serum TPS (tissue polypeptide-specific antigen) has been observed to be characteristic of carcinoma proliferation, and increased levels of TPS seem to be closely related to tumor progression. In this study we wanted to evaluate the importance of the tumormarker TPS in the diagnosis

Diagnostic and prognostic markers for hu
Diagnostic and prognostic markers for human prostate cancer
✍ Xiang Gao; Arthur T. Porter; David J. Grignon; J. Edson Pontes; Kenneth V. Honn πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 290 KB πŸ‘ 1 views

## BACKGROUND. The incidence and mortality of prostate cancer are increasing at alarming rates, partially due to an aging population. Early detection of prostate cancer, using clinically sensitive procedures and/or tumor markers (e.g., prostate-specific antigen [PSA]), is of prime importance. Howe

Sensitive serum markers for detecting pa
Sensitive serum markers for detecting pancreatic cancer
✍ Tetsuo Hayakawa; Takaharu Kondo; Tokimune Shibata; Hirotsugu Hamano; Motoji Kita πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 467 KB πŸ‘ 1 views
Use of neuroendocrine serum markers in t
Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate
✍ Angelsen, Anders; Syversen, Unni; Stridsberg, Mats; Haugen, Olav A.; MjΓΈlnerΓΈd, πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 274 KB πŸ‘ 1 views

Neuroendocrine (NE) differentiation of prostatic adenocarcinomas has received increasing attention in recent years as a result of possible implications on prognosis and therapy. The incidence of NE cells in tumors has been reported from 10% up to 100%. Several studies have shown chromogranin A (CgA)